Good
Partially Aligned
Patient Risk:
Moderate
Summary
Core disease/HR+/HER2− and prior-endocrine therapy concepts are supported, but the claims are phrased broadly and do not consistently include the label’s required qualifiers (postmenopausal women; HR+/HER2− advanced or metastatic; and the specific indication contexts).
Category Scores
Accurate Statements
Faslodex (fulvestrant) is used in hormone receptor–positive breast cancer.
Supported by 1 INDICATIONS AND USAGE (HR-positive breast cancer).
Faslodex (fulvestrant) is used in metastatic disease.
Supported by 1 INDICATIONS AND USAGE (HR-positive, HER2-negative advanced or metastatic breast cancer).
Faslodex (fulvestrant) is used after prior endocrine therapy.
Supported by 1 INDICATIONS AND USAGE (progression following endocrine therapy).
Unsupported Statements
Fulvestrant is marketed under the brand name Faslodex in many countries.
No marketing/territory statement is provided in the supplied label excerpts.
Faslodex (fulvestrant) is used in hormone receptor–positive breast cancer.
Partially supported as phrased: the label limits indication to HR-positive, HER2-negative advanced/metastatic breast cancer in postmenopausal women, and/or specifies additional context (e.g., postmenopausal not previously treated with endocrine therapy or progression after endocrine therapy; and combination regimens). The claim omits these required qualifiers.
Faslodex (fulvestrant) is used in metastatic disease.
Partially supported as phrased: the label specifies HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women (and additional labeled contexts). The claim omits HER2 status and postmenopausal population/context.
Faslodex (fulvestrant) is used after prior endocrine therapy.
Partially supported as phrased: the label ties this to HR-positive, HER2-negative advanced breast cancer in postmenopausal women with disease progression following endocrine therapy (and/or combination contexts). The claim omits HER2 status and postmenopausal qualification.
Fulvestrant is marketed under the brand name Faslodex in many countries.
Unsupported: label excerpt provided does not establish 'many countries' scope.
Contradictions
Important Omissions
Explicitly stating the label’s required qualifiers for the indication: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, and the specific labeled contexts (e.g., postmenopausal not previously treated with endocrine therapy; disease progression following endocrine therapy; and/or use in combination with ribociclib/palbociclib/abemaciclib).
Importance:
Moderate
The user’s set of claims includes 'contraindications/risks' broadly, but none of the provided bullet claims specifies the label’s contraindication content (hypersensitivity) or particular warnings/precautions (e.g., bleeding risk due to IM administration; embryo-fetal toxicity; injection-site neurologic events; estradiol immunoassay interference).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core disease context (HR-positive; advanced/metastatic; after endocrine therapy) aligns, the claims are broadly worded and omit label qualifiers (HER2-negative; postmenopausal; and specific indication contexts). Additionally, 'contraindications/risks' are referenced but not concretely specified, so a reader may miss label-specific safety requirements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Claims are phrased too generally and omit key label qualifiers (postmenopausal women; HR+/HER2−; and specific labeled prior-treatment/combination contexts). Also includes a marketing/territory statement not supported by the provided label excerpts.
Suggested Improvement
Rephrase indications to match 1 INDICATIONS AND USAGE (HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women; including progression following endocrine therapy and the specified combination indications). Limit safety/contraindication references to what is stated in the supplied labeling (e.g., hypersensitivity contraindication; specific warnings such as bleeding risk with IM administration and embryo-fetal toxicity), unless additional label text is provided.